| # | Title | Journal | Year | Citations |
|---|
| 1 | Benign Breast Disease and the Risk of Breast Cancer | New England Journal of Medicine | 2005 | 785 |
| 2 | Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival | Annals of Oncology | 2008 | 715 |
| 3 | Clinical Features of 5,628 Primary Lung Cancer Patients | Chest | 2005 | 386 |
| 4 | Folate receptor alpha as a tumor target in epithelial ovarian cancer | Gynecologic Oncology | 2008 | 365 |
| 5 | Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer | Journal of Clinical Oncology | 2005 | 328 |
| 6 | Folate receptor overexpression is associated with poor outcome in breast cancer | International Journal of Cancer | 2007 | 224 |
| 7 | The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer | Oncologist | 2007 | 218 |
| 8 | Genetic variants and risk of lung cancer in never smokers: a genome-wide association study | Lancet Oncology, The | 2010 | 218 |
| 9 | Primary salivary gland‐type lung cancer | Cancer | 2007 | 210 |
| 10 | In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417 | Cancer Research | 2006 | 186 |
| 11 | Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress | Blood | 2007 | 176 |
| 12 | Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma | Cancer Chemotherapy and Pharmacology | 2010 | 169 |
| 13 | The Insulin-Like Growth Factor System in Cancer | Endocrinology and Metabolism Clinics of North America | 2012 | 165 |
| 14 | Advances in Chemotherapy of Non-small Cell Lung Cancer | Chest | 2006 | 157 |
| 15 | International Brachytherapy Practice Patterns: A Survey of the Gynecologic Cancer Intergroup (GCIG) | International Journal of Radiation Oncology Biology Physics | 2012 | 149 |
| 16 | Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes | BMJ Open Diabetes Research and Care | 2019 | 137 |
| 17 | Central neurocytoma: Management recommendations based on a 35-year experience | International Journal of Radiation Oncology Biology Physics | 2007 | 132 |
| 18 | Histologic grade is an independent prognostic factor for survival in non–small cell lung cancer: An analysis of 5018 hospital- and 712 population-based cases | Journal of Thoracic and Cardiovascular Surgery | 2006 | 128 |
| 19 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? | Cancer Treatment Reviews | 2014 | 119 |
| 20 | COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials | Nature Reviews Clinical Oncology | 2021 | 103 |
| 21 | Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance | Oncogene | 2007 | 102 |
| 22 | The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons | Journal of Biological Chemistry | 2005 | 92 |
| 23 | The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin Reductase | Antioxidants and Redox Signaling | 2009 | 90 |
| 24 | The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative Mechanism | Cancer Journal (Sudbury, Mass ) | 2007 | 88 |
| 25 | Anti-angiogenic therapies for metastatic colorectal cancer | The Cochrane Library | 2009 | 80 |
| 26 | DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53 | Cell Death and Differentiation | 2016 | 80 |
| 27 | Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells | Molecular Oncology | 2015 | 70 |
| 28 | Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men | Mayo Clinic Proceedings | 2004 | 67 |
| 29 | Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia | Breast Cancer Research and Treatment | 2010 | 63 |
| 30 | Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer | Gynecologic Oncology | 2009 | 57 |
| 31 | Primary adenoid cystic carcinoma of the lung | Cancer | 2007 | 51 |
| 32 | Cixutumumab | Expert Opinion on Investigational Drugs | 2009 | 51 |
| 33 | A noncanonical AR addiction drives enzalutamide resistance in prostate cancer | Nature Communications | 2021 | 43 |
| 34 | Total scapulectomy and constrained reverse total shoulder reconstruction for a Ewing's Sarcoma | Journal of Surgical Oncology | 2009 | 40 |
| 35 | Annatto Constituent Cis-Bixin Has Selective Antimyeloma Effects Mediated by Oxidative Stress and Associated with Inhibition of Thioredoxin and Thioredoxin Reductase | Antioxidants and Redox Signaling | 2010 | 37 |
| 36 | Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy | Heliyon | 2018 | 37 |
| 37 | Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors | Investigational New Drugs | 2011 | 34 |
| 38 | Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer | Oncology | 2006 | 34 |
| 39 | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States | Cancers | 2021 | 33 |
| 40 | A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches | Breast Cancer Research and Treatment | 2007 | 31 |
| 41 | Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications | Oncologist | 2012 | 30 |
| 42 | Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy | Current Opinion in Investigational Drugs | 2009 | 28 |
| 43 | Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy | Clinical Gastroenterology and Hepatology | 2015 | 25 |
| 44 | A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors | Cancer Chemotherapy and Pharmacology | 2006 | 23 |
| 45 | Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study | Frontiers in Pharmacology | 2016 | 23 |
| 46 | Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression | Cancer Research | 2021 | 18 |
| 47 | Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924 | Molecular Cancer Therapeutics | 2011 | 17 |
| 48 | An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors | Cell Reports | 2021 | 17 |
| 49 | Clinical biomarkers of pulmonary carcinoid tumors in never smokers via profiling miRNA and target mRNA | Cell and Bioscience | 2014 | 15 |
| 50 | Corticosteroid and Cortisol Serum Levels Following Intra‐articular Triamcinolone Acetonide Lumbar Facet Joint Injections | Pain Practice | 2018 | 15 |
